Research
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i610 (Published 17 February 2016) Cite this as: BMJ 2016;352:i610Data supplement
Web Extra
- Data Supplement - Web appendix 1: Search strategies
- Data Supplement - Web appendix 2: Risk of bias of included randomised controlled trials
- Data Supplement - Web appendix 3: Supplementary forest plots
- Data Supplement - Web appendix 4: Risk of bias of included cohort studies
- Data Supplement - Web appendix 5: Risk of bias of included case-control studies
Related articles
- Editorial Published: 17 February 2016; BMJ 352 doi:10.1136/bmj.i801
- Editorial Published: 03 January 2008; BMJ 336 doi:10.1136/bmj.39386.664016.BE
- Letter Published: 24 May 2016; BMJ 353 doi:10.1136/bmj.i2920
See more
- Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysisBMJ December 05, 2016, 355 i6188; DOI: https://doi.org/10.1136/bmj.i6188
- NHS to fund large trial of pre-exposure prophylaxis for HIV preventionBMJ December 05, 2016, 355 i6537; DOI: https://doi.org/10.1136/bmj.i6537
- Bill to boost medical research funding and speed drug approval passes US houseBMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498
- Alpha blockers for treatment of ureteric stones: systematic review and meta-analysisBMJ December 01, 2016, 355 i6112; DOI: https://doi.org/10.1136/bmj.i6112
- Sixty seconds on . . . solanezumabBMJ November 29, 2016, 355 i6389; DOI: https://doi.org/10.1136/bmj.i6389
Cited by...
- Cardiovascular safety of evogliptin dual and triple therapy in patients with type 2 diabetes: a nationwide cohort study
- New Aspects of Diabetes Research and Therapeutic Development
- Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)
- Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications
- Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
- The Alchemists Nightmare: Might Mesenchymal Stem Cells That Are Recruited to Repair the Injured Heart Be Transformed Into Fibroblasts Rather Than Cardiomyocytes?
- Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity?: Clues From Laboratory Models and Clinical Trials
- Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis
- Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction
- Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis
- Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure
- Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis
- Trading Lower HbA1c for Increased Adverse Events: A Zero Sum Game?
- Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS
- Clinicians should think twice before prescribing DPP-4 inhibitors for diabetes
- Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2 diabetes
- Authors reply to Patel and colleagues